The success of anti-vascular endothelial growth factor (anti-VEGF) therapy and its use as first-line treatment for neovascular age-related macular degeneration has made intravitreal (IVT) injection a common dosing technique to deliver biologics in the eye1,2. The gene discussed is VEGFA; the disease is wet macular degeneration.